西班牙纳瓦拉 2022 年 5 月至 7 月期间针对 SARS-CoV-2 的抗体血清阳性率与 COVID-19 风险。
Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022.
机构信息
Instituto de Salud Pública de Navarra, Pamplona, Spain.
CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain.
出版信息
Euro Surveill. 2022 Aug;27(33). doi: 10.2807/1560-7917.ES.2022.27.33.2200619.
Abstract
In Navarre, Spain, in May 2022, the seroprevalence of anti-nucleocapsid (N) and anti-spike (S) antibodies of SARS-CoV-2 was 58.9% and 92.7%, respectively. The incidence of confirmed COVID-19 thereafter through July was lower in people with anti-N antibodies (adjusted odds ratio (aOR) = 0.08; 95% confidence interval (CI): 0.05-0.13) but not with anti-S antibodies (aOR = 1.06; 95% CI: 0.47-2.38). Hybrid immunity, including anti-N antibodies induced by natural exposure to SARS-CoV-2, seems essential in preventing Omicron COVID-19 cases.
摘要
2022 年 5 月，在西班牙纳瓦拉，针对 SARS-CoV-2 的核衣壳（N）和刺突（S）抗体的血清阳性率分别为 58.9%和 92.7%。此后，截至 7 月，有抗 N 抗体者的确诊 COVID-19 发病率较低（校正优势比[aOR] = 0.08；95%置信区间[CI]：0.05-0.13），但无抗 S 抗体者并非如此（aOR = 1.06；95%CI：0.47-2.38）。混合免疫，包括由 SARS-CoV-2 自然暴露引起的抗 N 抗体，似乎对预防奥密克戎 COVID-19 病例至关重要。
相似文献
1
Seroprevalence of antibodies against SARS-CoV-2 and risk of COVID-19 in Navarre, Spain, May to July 2022.西班牙纳瓦拉 2022 年 5 月至 7 月期间针对 SARS-CoV-2 的抗体血清阳性率与 COVID-19 风险。
Euro Surveill. 2022 Aug;27(33). doi: 10.2807/1560-7917.ES.2022.27.33.2200619.
2
Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021.根据 2020 年 7 月至 2021 年 5 月的献血样本，估计美国感染和疫苗引起的 SARS-CoV-2 血清流行率。
JAMA. 2021 Oct 12;326(14):1400-1409. doi: 10.1001/jama.2021.15161.
3
Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence, Japan, 2023.2023 年日本感染和疫苗诱导的 SARS-CoV-2 血清流行率。
Emerg Infect Dis. 2024 Jun;30(6):1267-1270. doi: 10.3201/eid3006.231454.
4
Mild SARS-CoV-2 Illness Is Not Associated with Reinfections and Provides Persistent Spike, Nucleocapsid, and Virus-Neutralizing Antibodies.轻度 SARS-CoV-2 感染与再感染无关，并提供持久的刺突、核衣壳和病毒中和抗体。
Microbiol Spectr. 2021 Oct 31;9(2):e0008721. doi: 10.1128/Spectrum.00087-21. Epub 2021 Sep 1.
5
Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease.单次免疫表达刺突蛋白和核衣壳蛋白的重组 ACAM2000 痘苗病毒可保护仓鼠免受 SARS-CoV-2 引起的临床疾病。
J Virol. 2022 May 11;96(9):e0038922. doi: 10.1128/jvi.00389-22. Epub 2022 Apr 12.
6
Seroprevalence of antibodies against SARS-CoV-2 in the Valencian Community (Spain) as of October 2022.截至 2022 年 10 月，西班牙巴伦西亚自治区（Valencian Community）针对 SARS-CoV-2 的抗体血清阳性率。
Gac Sanit. 2023 May 18;37:102312. doi: 10.1016/j.gaceta.2023.102312. eCollection 2023.
7
SARS-CoV-2 Seroprevalence Survey Estimates Are Affected by Anti-Nucleocapsid Antibody Decline.SARS-CoV-2 血清阳性率调查估计受到核衣壳抗体下降的影响。
J Infect Dis. 2021 Apr 23;223(8):1334-1338. doi: 10.1093/infdis/jiaa796.
8
Sustained SARS-CoV-2 nucleocapsid antibody levels in nonsevere COVID-19: a population-based study.非重症 COVID-19 患者中持续的 SARS-CoV-2 核衣壳抗体水平：一项基于人群的研究。
Clin Chem Lab Med. 2020 Nov 19;59(2):e49-e51. doi: 10.1515/cclm-2020-1347.
9
Cumulative incidence of SARS-CoV-2 infection in the general population of the Valencian Community (Spain) after the surge of the Omicron BA.1 variant.在奥密克戎 BA.1 变异株引发疫情高峰后，西班牙瓦伦西亚自治区（西班牙）普通人群中 SARS-CoV-2 感染的累积发病率。
J Med Virol. 2023 Jan;95(1):e28284. doi: 10.1002/jmv.28284. Epub 2022 Nov 11.
10
Seroprevalence of anti-SARS-CoV-2 antibodies in household domestic ferrets (Mustela putorius furo) in Spain, 2019-2023.2019-2023 年西班牙家庭养殖雪貂（Mustela putorius furo）中抗 SARS-CoV-2 抗体的血清流行率。
Vet Res Commun. 2024 Feb;48(1):533-540. doi: 10.1007/s11259-023-10190-2. Epub 2023 Aug 7.
引用本文的文献
1
Neutralizing antibody responses over time in a demographically and clinically diverse cohort of individuals recovered from SARS-CoV-2 acquisition in Africa: A cohort study.非洲从感染新冠病毒中康复的不同人口统计学和临床特征个体队列中随时间推移的中和抗体反应：一项队列研究
PLOS Glob Public Health. 2025 Sep 11;5(9):e0005156. doi: 10.1371/journal.pgph.0005156. eCollection 2025.
2
Longitudinal Follow-Up of the Specific Antibody Response to SARS-CoV-2 Vaccination in Colombia.哥伦比亚对新冠病毒疫苗接种特异性抗体反应的纵向随访
J Med Virol. 2025 Jan;97(1):e70133. doi: 10.1002/jmv.70133.
3
4
Evaluating Immunologic and Illness Outcomes of SARS-CoV-2 Infection in Vaccinated and Unvaccinated Children Aged ≥ 5 Years, in a Multisite Longitudinal Cohort.在一个多中心纵向队列中评估≥5岁接种和未接种疫苗儿童的SARS-CoV-2感染的免疫和疾病结局。
Diseases. 2024 Aug 1;12(8):171. doi: 10.3390/diseases12080171.
5
Prevalence of SARS-CoV-2-specific antibodies in a sample of the Lithuanian population-based study in Spring 2023.2023年春季立陶宛基于人群的研究样本中SARS-CoV-2特异性抗体的流行情况。
Heliyon. 2024 Apr 12;10(8):e29343. doi: 10.1016/j.heliyon.2024.e29343. eCollection 2024 Apr 30.
6
Seroepidemiological assessment of SARS-CoV-2 vaccine responsiveness and associated factors in the vaccinated community of the Casablanca-Settat Region, Morocco.摩洛哥卡萨布兰卡-塞塔特大区接种人群中 SARS-CoV-2 疫苗反应性及其相关因素的血清流行病学评估。
Sci Rep. 2024 Apr 3;14(1):7817. doi: 10.1038/s41598-024-58498-6.
7
Vaccinated COVID-19 Index Cases Are Less Likely to Transmit SARS-CoV-2 to Their Household Contacts: A Cohort Study.接种新冠疫苗的新冠病毒感染指数病例向其家庭接触者传播新冠病毒的可能性较小：一项队列研究。
Vaccines (Basel). 2024 Feb 26;12(3):240. doi: 10.3390/vaccines12030240.
8
Realistic Estimation of COVID-19 Infection by Seroprevalence Surveillance of SARS-CoV-2 Antibodies: An Experience From Korea Metropolitan Area From January to May 2022.通过SARS-CoV-2抗体血清流行率监测对COVID-19感染情况的实际估计：来自韩国首都地区2022年1月至5月的经验
J Korean Med Sci. 2024 Feb 5;39(5):e43. doi: 10.3346/jkms.2024.39.e43.
9
Seroprevalence of severe acute respiratory syndrome coronavirus 2 N antibodies between December 2021 and march 2023 in Japan.2021 年 12 月至 2023 年 3 月期间日本严重急性呼吸综合征冠状病毒 2 N 抗体的血清阳性率。
Epidemiol Infect. 2024 Jan 23;152:e24. doi: 10.1017/S0950268824000141.
10
Hospitalisations and Deaths Averted by COVID-19 Vaccination in Navarre, Spain, 2021-2022.2021 - 2022年西班牙纳瓦拉地区新冠疫苗接种避免的住院和死亡情况
Vaccines (Basel). 2024 Jan 7;12(1):58. doi: 10.3390/vaccines12010058.
本文引用的文献
1
Estimation of COVID-19 vaccine effectiveness against hospitalisation in individuals aged ≥ 65 years using electronic health registries; a pilot study in four EU/EEA countries, October 2021 to March 2022.利用电子健康记录估计≥65 岁人群中 COVID-19 疫苗对住院的有效性；2021 年 10 月至 2022 年 3 月在四个欧盟/欧洲经济区国家开展的一项试点研究。
Euro Surveill. 2022 Jul;27(30). doi: 10.2807/1560-7917.ES.2022.27.30.2200551.
2
Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections.既往感染和疫苗接种对奥密克戎感染症状的影响。
N Engl J Med. 2022 Jul 7;387(1):21-34. doi: 10.1056/NEJMoa2203965. Epub 2022 Jun 15.
3
Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022.2021 年 12 月至 2022 年 1 月期间，法国针对奥密克戎和德尔塔症状感染以及严重 COVID-19 结局的疫苗诱导和自然获得性保护。
Euro Surveill. 2022 Apr;27(16). doi: 10.2807/1560-7917.ES.2022.27.16.2200250.
4
Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden.具有自然免疫和混合免疫的个体中再次感染SARS-CoV-2和因COVID-19住院的风险：瑞典一项回顾性全人群队列研究
Lancet Infect Dis. 2022 Jun;22(6):781-790. doi: 10.1016/S1473-3099(22)00143-8. Epub 2022 Apr 1.
5
Population antibody responses following COVID-19 vaccination in 212,102 individuals.212102 例个体接种 COVID-19 疫苗后的人群抗体反应。
Nat Commun. 2022 Feb 16;13(1):907. doi: 10.1038/s41467-022-28527-x.
6
Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection.新冠病毒疫苗接种和既往感染后对 SARS-CoV-2 的保护作用。
N Engl J Med. 2022 Mar 31;386(13):1207-1220. doi: 10.1056/NEJMoa2118691. Epub 2022 Feb 16.
7
Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021.2021 年 11 月至 12 月，在挪威发生的由 SARS-CoV-2 奥密克戎变异株引起的疫情。
Euro Surveill. 2021 Dec;26(50). doi: 10.2807/1560-7917.ES.2021.26.50.2101147.
8
Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021.特定 COVID-19 疫苗对西班牙纳瓦拉密切接触者二次感染的有效性，2021 年 4 月至 8 月。
Euro Surveill. 2021 Sep;26(39). doi: 10.2807/1560-7917.ES.2021.26.39.2100894.
9
Estimated US Infection- and Vaccine-Induced SARS-CoV-2 Seroprevalence Based on Blood Donations, July 2020-May 2021.根据 2020 年 7 月至 2021 年 5 月的献血样本，估计美国感染和疫苗引起的 SARS-CoV-2 血清流行率。
JAMA. 2021 Oct 12;326(14):1400-1409. doi: 10.1001/jama.2021.15161.
10
Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021.2021 年 1 月至 4 月，西班牙纳瓦拉地区 COVID-19 疫苗预防 SARS-CoV-2 感染和住院的有效性。
Euro Surveill. 2021 May;26(21). doi: 10.2807/1560-7917.ES.2021.26.21.2100438.
Zotero 插件